About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, October 25th, 2017

The QualityStocks
Daily Stock List


Eguana Technologies, Inc. (EGTYF)

InvestorsHub reported on Eguana Technologies, Inc. (EGTYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Eguana Technologies, Inc. is one of the leaders in power conversion and control systems for distributed energy storage. The Company designs and manufactures high performance power controls for commercial and residential energy storage systems. It is the leading supplier of power controls for solar self-consumption, grid services, and demand charge applications at the grid edge. Eguana Technologies has its headquarters in Calgary, Alberta. The Company lists on the OTC Markets Group’s OTCQB.

Eguana Technologies has thousands of its proprietary energy storage inverters deployed in the European and North American markets. The Company’s vision is to become the foremost global supplier of intelligent power electronics for grid tied residential storage applications.

One of the leaders in power conversion and control systems for distributed energy storage, the Company delivers proven, durable, high quality solutions from its high capacity manufacturing facilities in Europe and North America. In addition, Eguana delivers grid edge power electronics for fuel cell, photovoltaic, and battery applications.

The Company has its AC Battery™. The Eguana AC Battery is a complete grid ready power control solution. It accepts dispatch commands from any control network employing open communication protocols. The AC Battery is built around Eguana’s patented Bi-Direx power controls.

The AC Battery is 'control' ready. It can be commanded through a Sunspec-compliant ModBus interface using any third-party energy management system. The AC Battery is an appropriate fit for small commercial and light industrial applications. It is compatible with all advanced battery technologies. This is from Lithium-Ion over Lead-Acid to Redox Flow, Liquid Metal, or Sodium-Ion chemistries.

The Company’s Patented "pulsed step wave" technology takes a different approach to lessening conducted losses through sharing the current across parallel bridges and recombining into the AC output waveform through an inventive transformer topology and advanced control software. The single power conversion step further reduces losses. It also allows faster and more stable control loops than conventional inverters.

Last week, Eguana Technologies announced its first volume shipment of AC Batteries to partner EGear LLC, representing roughly $1 million and ready for immediate installation upon receipt. Increasing availability of backordered battery modules will also allow Eguana to deliver a second volume shipment of equivalent size within the quarter with continued deliveries next year.

Mr. Justin Holland, Chief Executive Officer of Eguana Technologies, said, “Installations in Hawaii have continued and are ready to scale as AC Battery supply catches up to backordered demand. With the current orders backlog, and increasing sales from EGear, our expectation is to see quarter over quarter growth in Hawaii through 2018.”

Eguana Technologies, Inc. (EGTYF), closed Wednesday's trading session at $0.1631, down 4.62%, on 16,625 volume with 9 trades. The average volume for the last 60 days is 82,211 and the stock's 52-week low/high is $0.122/$0.267.

Biotricity, Inc. (BTCY)

Stock News Now, SmallCap Network, and SECFilings News reported earlier on Biotricity, Inc. (BTCY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Biotricity, Inc. is a medical diagnostic and consumer healthcare technology company based in Redwood City, California. Its dedication is to deliver biometric remote monitoring solutions. Biotricity delivers these solutions to the medical and consumer markets. This includes diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity lists on the OTC Markets Group’s OTCQB.

The Company’s vision is putting health management into the hands of the individual. It is working to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the rising burden on the healthcare system. Biotricity’s Research and Development (R&D) continues to concentrate on the preventative healthcare market.

Biotricity has created two ECG monitoring devices. The design of these is to improve upon the tools and devices now available in today’s market.

For Consumers, the Company has its Biolife. This is a preventative care solution. It takes advantage of the expertise gained from the Company’s Bioflux. The design of it is to help individuals track their progress in real-time so they can stay motivated to make lifestyle changes. Biolife helps users make lifestyle changes through uniting medically relevant ECG data with social media interactivity and a lifestyle log.

For Physicians, Biotricity has its Bioflux. This is a medical technology solution for physicians to test and diagnose patients, and benefit from a unique system that provides continuous active monitoring for up to 30 consecutive days.

Bioflux consists of an ECG monitoring device, software, as well as access to a monitoring lab. The Bioflux software component is an acquisition that is already Food and Drug Administration (FDA) cleared. It is a standard for ECG monitoring in cardiac clinics and hospitals.

Biotricity has partnered with Global to Local (G2L). G2L is an organization committed to providing programs that improve individual and community health outcomes, expands access to healthcare services, and empowers economic development in the most diverse and underserved communities. The collaboration between Biotricity and G2L will initially focus on building distinctive solutions for outcome measurements for individuals suffering from chronic disease.

In early September, Biotricity announced that it received comments from the FDA on its hardware 510(k) submission. The FDA is requesting that the Company conduct more biocompatibility testing of the external pouch used by patients to carry the Bioflux device. Biotricity said it is confident in the material used because it has previously passed cytotoxicity testing that was conducted in accordance with FDA guidelines.

The Company has started the testing process. However, it is prepared to change the material, if required. Testing usually takes 6 to 8 weeks. The testing is taking place at an independent lab.

Biotricity, Inc. (BTCY), closed Wednesday's trading session at $2.70, up 31.07%, on 75,306 volume with 139 trades. The average volume for the last 60 days is 1,226 and the stock's 52-week low/high is $1.81/$3.00.

IEG Holdings Corp. (IEGH)

MissionIR, DreamTeamNetwork, OTC Markets Group, SeeThruEquity Research, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, and Penny Stock Bets reported previously on IEG Holdings Corp. (IEGH) and we report on the Company as well, here at the QualityStocks Daily Newsletter.

IEG Holdings Corp. provides online $5,000 and $10,000 unsecured consumer loans under the brand name, "Mr. Amazing Loans." The Company does so by way of its web portal www.mramazingloans.com. Loans are offered online in the United States through the Company's state licensed operating subsidiary Investment Evolution Corporation. IEG Holdings has its head office in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

IEG’s “Mr. Amazing Loans” is a leading Fintech company (Better Business Bureau accredited). “Mr. Amazing Loans” specializes in the above-mentioned $5,000 and $10,000 online unsecured personal loans.

Mr. Amazing Loans has no prepayment penalties or hidden fees. One can start paying off their personal loan for less than $38 a week. Personal loans are available for any purpose, with low interest and affordable repayments.

IEG Holdings originates consumer loans in Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri, Nevada, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Texas, Utah, and Wisconsin. It does so  via its online platform and distribution network.

IEG Holdings is a licensed direct lender. It has state licenses and/or certificates of authority to lend in the aforementioned 19 states. The Company provides all loans within the prevailing statutory rates.

Last month, IEG Holdings announced that it provided an additional $785,000 in new consumer loans over the July/August 2017 period. Since January 2015, cumulative loan volume has grown by 173.5 percent from $5,549,023 to $15,179,023 as of August 31, 2017.

Mr. Paul Mathieson, IEG Holdings' Chairman and Chief Executive Officer, said, "I am pleased to announce the re-acceleration of our loan volume growth utilizing part of the cash received from our sale of the One Main Holdings, Inc. shares acquired in the tender offer that closed in mid-June. We expect to deploy more of our cash to further increase new loan volume and resulting revenues over the remainder of the year."

IEG Holdings Corp. (IEGH), closed Wednesday's trading session at $0.325, down 15.58%, on 56,371 volume with 14 trades. The average volume for the last 60 days is 28,148 and the stock's 52-week low/high is $0.14/$8.60.

Sugarmade, Inc. (SGMD)

SmallCapVoice, Real Pennies, TopPennyStockMovers, Promotion Stock Secrets, and TheMicrocapNews reported previously on Sugarmade, Inc. (SGMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sugarmade, Inc. is a product and brand marketing company listed on the OTC Markets’ OTCQB. The Company established in 2010. Sugarmade also involves in the manufacture and marketing of environmentally friendly tree free paper for home and office environments under the Sugarmade brand name. Sugarmade paper is 100 percent tree free made, primarily of sugarcane waste, called bagasse. Sugarmade has its corporate office in City of Industry, California.

Sugarcane fiber, bagasse, is a discarded by-product of sugar production. Bagasse is denser in cellulose fiber than wood pulp. It produces the same amount of paper with fewer raw materials, less water, less energy, and less waste. The final product is a strong, ultra-white office paper. This paper is 100 percent biodegradable, compostable, and also recyclable.

Sugarmade's brands include BudLife, CaliGrownSupplies.com, CarryOutSupplies.com, FreeHand ThumbTray, and Sriracha Seasoning Stix. Sriracha is an innovative culinary seasoning product.

CarryOutSupplies.com is Sugarmade’s oldest business division. It supplies custom and generic printed paper products to over 2,000 quick service restaurants (QSRs). CarryOutSupplies.com provides generic and printed paper and other products to take-out food establishments and restaurants.

CaliGrownSupplies.com is the new division of the Company. It targets the fast-growing hydroponic supply sector. The focus of this business unit is on business-to-business (B2B) e-commerce, and manufacturing and distribution of hydroponic-related supplies.

Sugarmade has signed an exclusive distribution agreement with privately held Plantation Corp. for its inventive preservation technology based on radical integration of specialized gases and natural agents that significantly extends the useful life of medical marijuana up to six months through monitoring the internal containers environment and automatically adjusting its atmosphere as needed; all without the need for refrigeration.

Sugarmade has its BudLife Intelligent Cannabis Container System brand identity.  BudLife products, based on patented technology, will be launched, as a new, pioneering category in intelligent packaging to deliver all the benefits of preservation and stability to cannabis without the requirement for refrigeration.

Recently, Sugarmade and Plantation Corp. announced important breakthroughs in long-term cannabis storage. Laboratory research has produced an optimum proprietary packaging atmosphere. It will permit long-term storage of cannabis in the new BudLife containers. Plantation has come up with what it believes is the optimum storage atmosphere for cannabis flowers. BudLife products will preserve the important properties of cannabis. These properties are THC levels, terpene quality, and tricome structure, along with aroma and feel.

Sugarmade and Plantation are currently working towards finalizing the packing design. Based on these breakthroughs, the two companies expect to start taking orders for BudLife in Q4 2017. This month, Sugarmade and Plantation unveiled the prototype design for BudLife.

Sugarmade, Inc. (SGMD), closed Wednesday's trading session at $0.0347, up 2.06%, on 375,449 volume with 28 trades. The average volume for the last 60 days is 1,317,172 and the stock's 52-week low/high is $0.0219/$0.42.

BioRestorative Therapies, Inc. (BRTX)

Investor Ideas, Streetwise Reports, and ProActive Capital reported previously on BioRestorative Therapies, Inc. (BRTX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BioRestorative Therapies, Inc. is a life sciences company centering on adult stem cell-based therapies for different personal medical applications. The Company develops products and medical procedures using cell and tissue protocols, chiefly involving adult stem cells. BioRestorative’s aim is to become a leader in providing medical procedures utilizing cell and tissue protocols, mainly involving adult stem cells (non-embryonic), and allowing patients to undergo minimally invasive cellular-based treatments. BioRestorative Therapies has its corporate, administrative, and laboratory operations in Melville, New York.

BioRestorative’s products and medical procedures include brtxDISC™ (Disc Implanted Stem Cells), its Disc/Spine Program, and ThermoStem®, its Metabolic Program. brtxDISC™ is an investigational non-surgical treatment for bulging and herniated lumbar discs. brtxDISC™’s intention is for patients who have failed non-invasive procedures and face the prospect of surgery.

ThermoStem® is a treatment using brown fat stem cells. ThermoStem® is under development for metabolic disorders. This includes diabetes and obesity. The Company is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to produce brown adipose tissue (BAT). The intention of BAT is to mimic naturally occurring brown adipose depots, which regulate metabolic homeostasis in humans.

The Company’s lead cell therapy candidate is BRTX-100. This product is formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow.

BioRestorative Therapies is the beneficiary of a patent granted for a licensed curved needle device (CND). The design of it is to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair. The Company’s intention is to advance the design of this curved needle device to facilitate the delivery of substances, including living cells, to specific locations within the body and lessen the potential for damage to neighboring structures.

Earlier this month, BioRestorative Therapies announced that an independent lower back pain study was published in the Journal of Translational Medicine, featuring the Company’s licensed technologies for the treatment of lumbar degenerative disc disease.

The study was by a physician group based in Colorado. The study, entitled “Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy,” reported considerable improvements in pain and function and also overall subjective improvement.

Last week, BioRestorative Therapies announced that the Japan Patent Office issued the Company a Notice of Allowance on its patent application for a method of generating brown fat stem cells, related to its metabolic (ThermoStem®) program. This will be the third patent issued for BioRestorative’s brown fat metabolic technology. This patent follows a patent the Company was issued in the U.S. in November of 2015 and one in Australia in April of this year.

Upon issuance in Japan, the final patent will allow for a method of isolating and differentiating a non-embryonic human brown adipose-derived stem cell into functional human brown adipocytes and a method of identifying compounds that modifies metabolic activity of human brown adipocytes.

BioRestorative Therapies, Inc. (BRTX), closed Wednesday's trading session at $3.50, up 2.94%, on 5,500 volume with 8 trades. The average volume for the last 60 days is 1,250 and the stock's 52-week low/high is $2.70/$5.01.

Patriot Gold Corp. (PGOL)

Real Pennies, OtcWizard, Gold Investment Letter, and Standout Stocks reported earlier on Patriot Gold Corp. (PGOL), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Patriot Gold Corp. is a precious metals exploration and production company. Its corporate mission is to discover and develop significant gold and silver assets in Arizona and Nevada. Currently, Patriot Gold holds a portfolio of four projects. These are the Moss project in Arizona and three in Nevada (Bruner, Vernal, and Windy Peak). Patriot Gold is based in Las Vegas, Nevada.

Patriot Gold holds a 3 percent royalty in the Moss Mine in Arizona, an interest in the Bruner gold project in Nevada, and a 100 percent interest in the Vernal and Windy Peak projects in Nevada.

The Moss Mine Project is within the historic Oatman District, 10 miles east of Bullhead City, Arizona and about 70 miles southeast of Las Vegas. The Moss Mine is owned by Northern Vertex Mining Corp.

On April 20, 2017, Northern Vertex confirmed receipt of the final permitting document required before the start of commercial production (Aquifer Protection Permit signed by Water Quality Division Arizona Department of Environmental Quality). All operating permits have now been received. The Moss Mine is scheduled to enter production before year-end 2017.

The Bruner gold project property is approximately130 miles east-southeast of Reno, Nevada at the northern end of the Paradise Range and 45 miles northwest of the Round Mountain Mine. Patriot owns a 2 percent royalty in the Bruner gold project in Nevada. The Bruner gold project is owned by Canamex Resources Corp.

The Windy Peak Gold Project comprises 79 unpatented mineral claims in the Fairview mining district in southwest Nevada. Windy Peak is easily accessed, and is about 45 miles southeast of Fallon and 6 miles from Middlegate.

Patriot Gold’s Vernal gold project is in its early stage. The property is roughly 140 miles east-southeast of Reno, Nevada on the west side of the Shoshone Mountains. The property comprises 12 unpatented mining claims (240 acres).

The Bruner and Vernal gold projects are within Nevada's Walker Lane, which hosts many major deposits. These include the Goldfield (more than 5 million ounces of post production and present reserves) and the Comstock (more than 8 million ounces).

In September, Patriot Gold announced that it filed a National Instrument 43-101 Technical Report pertaining to its 100 percent owned Vernal project in Nye County, Nevada. The Vernal project is an early stage gold exploration project. The Report is an independent review and evaluation of the geology and mineralization of the Vernal project. This includes all exploration work carried out so far.

Patriot Gold Corp. (PGOL), closed Wednesday's trading session at $0.11, up 1.95%, on 1,400 volume with 1 trade. The average volume for the last 60 days is 19,049 and the stock's 52-week low/high is $0.0693/$0.1395.

BioHiTech Global, Inc. (BHTG)

MarketWatch, Zacks, and TradingView reported on BioHiTech Global, Inc. (BHTG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioHiTech Global, Inc. is a green technology business whose shares trade on the OTCQB. The Company provides innovative data-driven solutions for food waste disposal. It develops and deploys unique and disruptive waste management technologies. BioHiTech Global is a leader in zero waste solutions for businesses and municipalities of all sizes. The Company is based in Chestnut Ridge, New York.

BioHiTech Global provides waste management solutions to an international customer base encompassing a complete set of technology-based disposal options, which can have a substantial impact on waste generation. This is while providing a true zero landfill environment.

The Company collaborated with Natural Systems Utilities to convert commercial food waste to energy. In addition, it launched BioHiTech Cirrus. This is a mobile application (app) for consummate insight into the waste stream.

Moreover, BioHiTech Global has launched its BioHiTech Alto™. This is a next generation interactive industrial communication technology. It allows users to communicate intelligently with industrial equipment in real-time. BioHiTech Alto is an important new element of the Company’s complete food waste solution, which uses data and analytics to help drive smarter business decisions.

BioHiTech Global expanded its waste stream product offering in 2016 with the launch of Entsorga North America. The Entsorga North America undertaking expands the Company’s product offering towards providing disruptive, clean technology solutions that progress the worldwide movement towards sustainability and zero waste initiatives.

Entsorga North America will manage Apple Valley Waste Conversions LLC, which is an Entsorga North America part-owned subsidiary, the company that holds an exclusive license to deploy the proprietary Entstorga HEBioT Mechanical Biological Treatment (MBT) technology across the northeastern United States. The HEBioT MBT system converts food waste, plastics, and other carbon-based materials from the mixed municipal solid waste (MSW) stream into an Environmental Protection Agency (EPA) recognized alternative fuel source.

BioHiTech Global has started a strategic rollout plan for the deployment of its proprietary MBT Technology for Waste Disposal and Recycling. Its intention (the initial phase of its rollout strategy) is to locate two HEBioT facilities in the Northeast U.S. It entered into Letters of Intent (LOIs) to purchase property and solid waste permits for the two planned locations.

The proprietary HEBioT process recovers close to 80 percent of municipal solid waste. BioHiTech Global also intends to purchase an equity interest in the first ever HEBioT facility in the U.S., now under construction in Martinsburg, West Virginia.

This past August, BioHiTech Global announced the launch of BHTG Smart Mode. This is a new technology for the Company’s Eco-Safe Digester® and Revolution Series™ Digester lines of on-site food waste disposal equipment. Smart Mode takes advantage of cloud computing, machine learning, and the on-board internet-connected computer in the digester to intelligently drive the equipment to optimize performance and lessen servicing downtime.

In September, BioHiTech Global announced it started customer delivery of its Revolution Series Digesters. The initial shipments represent the first units received from the Company's earlier announced 100-unit production run order placed in June of this year. BioHiTech Global expects to progressively ship its new Revolution Series Digesters throughout the remainder of this year as additional units from this initial production run are received.

Last week, BioHiTech Global announced that it expects to complete delivery of 13 Revolution Series Seed Digesters this month. This is to fulfill an initial multi-unit rental order from a specialty grocery chain with more than 250 locations across the U.S.

BioHiTech Global, Inc. (BHTG), closed Wednesday's trading session at $6.03, up 3.97%, on 27,507 volume with 78 trades. The average volume for the last 60 days is 36,947 and the stock's 52-week low/high is $1.50/$9.50.


The QualityStocks
Company Corner


AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.0129, up 7.50%, on 1,259,750 volume with 19 trades. The stock’s average daily volume over the past 60 days is 156,259 and its 52-week low/high is $0.002/$0.04.

AppSwarm, Inc. (SWRM) ("the Company"), a technology company specializing in the accelerated development and publishing of mobile apps, has entered into a Letter of Intent with SinglePoint (SING) to conduct a shared roll-out of mobile applications specifically geared to the cannabis industry. The applications will be modeled and marketed under SinglePoint's SingleSeed subsidiary (www.SingleSeed.com), while AppSwarm (www.app-swarm.com) will provide the necessary technical support and application development.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

AppSwarm and SinglePoint Sign LOI to Conduct a Shared Roll-Out of Mobile Applications Specifically Geared to the Cannabis Industry

AppSwarm and SinglePoint Sign LOI to Launch Cannabis-Focused Applications

AppSwarm, Inc. Announces Joint Venture with Last-Mile Delivery Firm Estorerunner

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0596, up 0.10%, on 2,653,842 volume with 195 trades. The stock’s average daily volume over the past 60 days is 16,905,239, and its 52-week low/high is $0.0075/$0.415.

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of CNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, "Bitcoin's Recent Gains Spell Opportunity for Cryptocurrency Companies," shines a light on the current demand for alternative investment options. To view the full publication, visit: https://www.cannabisnewswire.com/bitcoins-recent-gains-spell-opportunity-cryptocurrency-companies/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

CannabisNewsWire Announces Publication Highlighting Investment Opportunities in Cryptocurrency

SinglePoint and AppSwarm Sign LOI to Launch Cannabis-Focused Applications

SinglePoint Completes Acquisition of Profitable Denver Colorado-Based Company

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.318, off by 8.12%, on 727,353 volume with 345 trades. The stock’s average daily volume over the past 60 days is 499,350, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals," discusses companies working to produce high-quality, consistent cannabinoids. To view the full publication, visit: https://www.networknewswire.com/biosynthesis-revolutionizing-cannabinoid-pharmaceuticals/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication on the Impact of Biosynthesis on Cannabinoid Pharmaceuticals

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid

InMed Updates Pain Program


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $0.65, up 24.98%, on 33,910 volume with 36 trades. The stock’s average daily volume over the past 60 days is 13,391, and its 52-week low/high is $0.49/$5.45.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO Labs Expands to Fifth Oregon Location

EVIO Labs Sees Demand for Testing Services Double

EVIO, Inc. (EVIO) is “One to Watch”

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.54, up 8.00%, on 93,581 volume with 31 trades. The stock’s average daily volume over the past 60 days is 58,688 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Announces Additional Deployment of Disruptive Surgical Information Software at Three Leading Hospitals in Southern California

ORHub, Inc. Appoints Industry-Leading Neurosurgeon and Orthopedic Surgeon to Advisory Board

ORHub, Inc. Welcomes Internationally Recognized Spine Surgeon to its Advisory Board

92 Resources Corp. (TSX.V:NTY) (OTCQB:RGDCF) (FSE:R9G2)

The QualityStocks Daily Newsletter would like to spotlight 92 Resources Corp. (RGDCF). Today, 92 Resources Corp. closed trading at $0.091, up 13.75%, on 7,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 24,395 and its 52-week low/high is $0.071/$0.115.

92 Resources Corp. (TSX.V: NTY) (OTCQB: RGDCF) is a modern energy solutions company focused on acquiring and advancing strategic and prospective energy-related projects in Canada. Its three principal assets include the Hidden Lake Lithium Property in the Northwest Territories, the Pontax Lithium Property in Quebec, and the Golden Frac Sand Property in British Columbia.

Preliminary mineralogy work on samples taken of the Hidden Lake pegmatites indicate spodumene – the world's richest source of lithium – is of a high quality and near the maximum theoretical limit. Scoping testwork saw an overall lithium extraction of 97 percent from the concentrate produced from these pegmatites, which means standard lithium extraction techniques can be applied, making the extraction of lithium easier and more cost effective.

92 Resources is focused on developing the lithium-rich resources located within its properties through open-pit mining and relatively straight-forward mineral processing procedures. Surface exploration programs that include prospecting, mapping and sampling of known spodumene-bearing pegmatites on the Hidden Lake property suggests the existence of one massive, interconnected body of pegmatite below the surface. Recent acquisitions of prospective hard-rock lithium properties in Quebec add to the company's impressive and growing asset portfolio.

Recent acquisitions of prospective hard-rock lithium properties in Quebec add to the company's impressive and growing asset portfolio. The properties, known as Corvette, Eastmain and Lac Du Beryl, consist of a combined 115 mineral claims totaling approximately 14,710 acres with confirmed pegmatite outcrops visible at each location. Some sampling has been completed at the Corvette property and shows spodumene crystals present, making this location a high priority for follow up work. Analytical results are pending on samples taken from known pegmatite outcrops visible at each property.

Lithium is a strategic, green metal used in batteries, electronics, electric vehicles, ceramics, alloys, lubricants and pharmaceuticals. The world market for electric vehicles, with China as its biggest customer, is exponentially growing as the demand for clean, renewable energy sources increases. A recent report by Grand View Research, Inc. places the lithium-ion battery market worldwide at $93 billion by 2025, with a compound annual growth rate of 17%.

92 Resources is led by an experienced management team and advisors with decades of expertise in market strategies, corporate development, mineral exploration and energy development. With an excellent team of professionals and promising mining projects, the company is well positioned to capitalize on the ever-rising demand for lithium. Disclaimer

92 Resources Corp. Blog

92 Resources Corp. News:

NetworkNewsWire Announces Publication Discussing the Impact of Lithium Demand on Several Public Companies

Lithium, Fuelling the New Millennium

92 Resources Corp. Acquires Three New Properties in Quebec

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.405, off by 1.22%, on 29,496 volume with 27 trades. The stock’s average daily volume over the past 60 days is 107,527 and its 52-week low/high is $0.1701/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(FFPM) +366.67%


(BTCY) +31.07%


(EVIO) +24.98%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251